A Randomized, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients With Relapsing Multiple Sclerosis
Phase of Trial: Phase III
Latest Information Update: 15 Mar 2018
At a glance
- Drugs Ofatumumab (Primary) ; Teriflunomide
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms ASCLEPIOS I
- Sponsors Novartis
- 26 Feb 2018 Planned End Date changed from 1 Jul 2019 to 16 May 2019.
- 27 Jun 2017 Trial desing for two parallel adaptive design studies presented at the 3rd Congress of the European Academy of Neurology
- 05 Jun 2017 Planned primary completion date changed from 1 Jul 2019 to 15 May 2019.